Rahmouni Alain, Montazel Jean-Luc, Divine Marine, Lepage Eric, Belhadj Karim, Gaulard Philippe, Bouanane Mohamed, Golli Mondher, Kobeiter Hicham
Department of Radiology, Centre Hospitalo-Universitaire Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France.
Radiology. 2003 Dec;229(3):710-7. doi: 10.1148/radiol.2293020748. Epub 2003 Oct 30.
To evaluate gadolinium enhancement of bone marrow in patients with lymphoproliferative diseases and diffuse bone marrow involvement.
Dynamic contrast material-enhanced magnetic resonance (MR) imaging of the thoracolumbar spine was performed in 42 patients with histologically proved diffuse bone marrow involvement and newly diagnosed myeloma (n = 31), non-Hodgkin lymphoma (n = 8), or Hodgkin disease (n = 3). The maximum percentage of enhancement (Emax), enhancement slope, and enhancement washout were determined from enhancement time curves (ETCs). A three-grade system for scoring bone marrow involvement was based on the percentage of neoplastic cells in bone marrow samples. Quantitative ETC values for the 42 patients were compared with ETC values for healthy subjects and with grades of bone marrow involvement by using mean t test comparisons. Receiver operating characteristic (ROC) analysis was conducted by comparing Emax values between patients with and those without bone marrow involvement. Baseline and follow-up MR imaging findings were compared in nine patients.
Significant differences in Emax (P <.001), slope (P <.001), and washout (P =.005) were found between subjects with normal bone marrow and patients with diffuse bone marrow involvement. ROC analysis results showed Emax values to have a diagnostic accuracy of 99%. Emax, slope, and washout values increased with increasing bone marrow involvement grade. The mean Emax increased from 339% to 737%. Contrast enhancement decreased after treatment in all six patients who responded to treatment but not in two of three patients who did not respond to treatment.
Dynamic contrast-enhanced MR images can demonstrate increased bone marrow enhancement in patients with lymphoproliferative diseases and marrow involvement.
评估钆增强在患有淋巴增殖性疾病且骨髓弥漫性受累患者中的情况。
对42例经组织学证实有骨髓弥漫性受累且新诊断为骨髓瘤(n = 31)、非霍奇金淋巴瘤(n = 8)或霍奇金病(n = 3)的患者进行胸腰椎的动态对比剂增强磁共振(MR)成像。从增强时间曲线(ETC)确定最大增强百分比(Emax)、增强斜率和增强廓清。基于骨髓样本中肿瘤细胞的百分比建立了一个三级骨髓受累评分系统。通过均值t检验比较,将42例患者的定量ETC值与健康受试者的ETC值以及骨髓受累分级进行比较。通过比较有骨髓受累和无骨髓受累患者之间的Emax值进行受试者操作特征(ROC)分析。对9例患者的基线和随访MR成像结果进行了比较。
正常骨髓受试者与骨髓弥漫性受累患者之间在Emax(P <.001)、斜率(P <.001)和廓清(P =.005)方面存在显著差异。ROC分析结果显示Emax值具有99%的诊断准确性。Emax、斜率和廓清值随着骨髓受累分级的增加而增加。平均Emax从339%增加到737%。在所有6例对治疗有反应的患者中,治疗后对比增强降低,但在3例对治疗无反应的患者中有2例未降低。
动态对比增强MR图像可显示淋巴增殖性疾病和骨髓受累患者骨髓增强增加。